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This study determined the expression of microRNA-133a (MiR-133a) in colorectal cancer (CRC) and adjacent normal mucosa
samples and evaluated its clinicopathological role in CRC. The expression of miR-133a in 125 pairs of tissue samples was analyzed
by quantitative real-time polymerase chain reaction (qRT-PCR) and correlated with patient’s clinicopathological data by statistical
analysis. Endogenous expression levels of several potential target geneswere determined by qRT-PCR and correlated using Pearson’s
method. MiR-133a was downregulated in 83.2% of tumors compared to normal mucosal tissue. Higher miR-133a expression in
tumor tissues was associated with development of distant metastasis, advanced Dukes and TNM staging, and poor survival. The
unfavorable prognosis of higher miR-133a expression was accompanied by dysregulation of potential miR-133a target genes, LIM
and SH3 domain protein 1 (LASP1), Caveolin-1 (CAV1), and Fascin-1 (FSCN1). LASP1 was found to possess a negative correlation
(𝛾 = −0.23), whereas CAV1 exhibited a significant positive correlation (𝛾 = 0.27), and a stronger correlation was found in patients
who developed distantmetastases (𝛾 = 0.42). In addition, a negative correlation of FSCN1was only found in nonmetastatic patients.
In conclusion, miR-133a was downregulated in CRC tissues, but its higher expression correlated with adverse clinical characteristics
and poor prognosis.
1. Introduction
Alone, colorectal cancer (CRC) is responsible for 600,000
mortalities annually and approximately 1.2 million new cases
are reported each year [1]. This makes CRC the 3rd most
common cancer worldwide and the 2nd leading cause of
cancer-related deaths in Europe and USA [2]. The sporadic
occurrence of CRC is a combinative effect of environmental
and genetic factors leading to themultistage progression from
normal to adenoma and then finally to malignant carcinoma
over several years to decades [3]. In approximately 20%
of cases, there is a strong genetic component involved as
first-degree relatives are diagnosed with the same cancer
or they have an underlying genetic predisposition (e.g.,
diabetes mellitus, obesity, gender, and inflammatory bowel
disease) that increases the risk of CRC. The main important
extrinsic factor is lifestyle. In particular, diet with high intake
of alcohol, red-meat and fat, and insufficient fiber uptake
increases the risk for CRC [4].
MiRNAs are highly conserved, small, noncoding RNA
approximately 19–25 nucleotides in length, with each capable
of regulating hundreds of genes and acting as key regulators
potentially affecting the expression of oncogenes and tumor
suppressors [5]. They function by targeting multiple tran-
scripts to epigenetically modulate the gene translation rate
and induce messenger RNA (mRNA) degradation depend-
ing on the strength of binding to 3󸀠 untranslated region
(3󸀠UTR). Their importance is highlighted by the fact that
they are involved in almost all essential biological cellular
processes including apoptosis, differentiation, proliferation,
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and migration, and they are suggested to regulate more than
50% of all protein-coding genes [6]. Within the Wellcome
Trust Sanger Institute, release 20, in June 2013, 1872 sequences
of human miRNAs have been identified thus far [7].
The potential for miRNAs as epigenetic biomarkers has
long been recognized as a noninvasive method for early CRC
detection to enable more effective therapeutic intervention
and evaluation of survival [8]. However, the exactmechanism
of miRNA dysregulation in CRC pathogenesis is not fully
understood, but unique sets of miRNA expression profiles
have been identified in a vast array of cancers, for example,
ovarian, breast, and prostate. The changes in this profile
during therapeutic response and disease progression provide
the potential for the advancement in cancer treatments [6].
MiR-133a has been reported on several occasions to be
downregulated in cancerswhen compared to normal adjacent
tissue, and it has been implemented as a tumor suppressor tar-
geting several oncogenes. MiR-133a targets FSCN1 in bladder
cancer and CAV1 in head and neck squamous cell carcinoma
functioning as a tumor suppressor [9, 10]. Many published
papers involving miRNAs array data showed that miR-133a
was underexpressed in CRC when compared to normal adja-
cent tissue, and miR-133a has also been documented to target
LASP1 through themitogen-activated protein kinase pathway
(MAPK) [11]. In breast cancer, the loss ofmiR-133a expression
has been associated with poor survival, and restoration of
this expression was found to reduce cell invasion in breast
cancer cell-lines and also regulate proliferation by targeting
epidermal growth factor receptor [12].
2. Materials and Methods
2.1. Patients and Tissue Samples. The study included 125
patients (age 29–95 years, mean age of 71.8 years) with
primary CRC diagnosed and resected at the Department
of Surgery, Queen Mary Hospital, Hong Kong, between
the years 2008 and 2012. For each case, samples from
primary tumor and the corresponding normal colorectal
mucosa were retrieved for comparison. All samples were
flash-frozen in liquid nitrogen and stored at −80∘C until
further molecular analysis. Written consent was received for
all patients who were recruited. The clinical and pathological
data was obtained from the hospital records relating to age,
gender, diagnosis, tumor location and size, TNM staging,
local invasion, differentiation, and distant metastasis. U6
small nuclear RNA (U6) and small nucleolar RNA, C/D
Box 48 (RNU48), were used as potential references genes
and U6 was used for further analysis. Expression levels were
“normalized” using small nuclear RNA U6 which has been
used by many other studies. This study was approved by the
Institutional Review Board of the hospital.
2.2. RNA Extraction and Quantitative RT-PCR. TaqMan
microRNA assay (Applied Biosystems, Foster City, CA) was
used to relatively quantify and detect the miRNA levels
of miR-133a (assay ID. 002246); U6 (Assay ID. 001973)
and RNU48 (Assay ID. 001006) were utilized as internal
controls. Total RNA was extracted from tumor tissue and
adjacent normal mucosa using mirVana miRNA isolation
Kit (Ambion, Austin, TX) according to the manufacturer’s
instructions. The RNA concentrations were measured using
Nanodrop ND-1000 spectrophotometer (Nanodrop Tech-
nologies, Wilmington, DE, USA).
This total RNA was used to reverse transcribe mRNA
complementary DNA (cDNA) and miRNAS using TaqMan
Microarray Assays (Applied Biosystems, Foster City, CA)
from 125 patient’s tissue samples. Each reverse transcriptase
reaction utilized 10 ng of total RNA (5.00𝜇L), 0.15 𝜇L dNTP
(100mM total), 1.00 𝜇L Multiscribe RT enzyme (50U/𝜇L),
1.50 𝜇L 10XRT buffer, 0.19 𝜇L RNase Inhibitor (20U/𝜇L),
4.16 𝜇L nuclease free water, and 3 𝜇L 5XRT primer making
a total reaction volume to 15 𝜇L. Takara PCR thermal cycler
DICE was programmed as follows: 30min at 16∘C, 30min
at 42∘C, and 5min at 85∘C. Real-time PCR was performed
using real-time PCR 7900HT system (Applied Biosystems,
Foster City, CA).The reversely transcribed cDNAwas diluted
1 : 20 before the qPCR reaction volumewasmixed and 1.33 𝜇L
was combined with 10 𝜇L 2X Universal PCR Master Mix (no
AmpErase UNG), 7.67 𝜇L water, and 1.0 𝜇L 20X MicroRNA
Assay. A total volume of 20𝜇L per reaction was transferred to
a 96-well MicroAmp plates (Applied Biosystems, Foster City,
CA) and incubated for 10min at 95∘C, followed by 40 cycles
at 95∘C for 15 sec. and then 60∘C for 60 sec. All samples were
run in duplicate.
For miR-133a, the primers were as follows: forward, 5󸀠-
UUUGGUCCCCUUCAACCAGCUG-3󸀠 and reverse, 5󸀠-
UAAACCAAGGUAAAAUGGUCGA-3󸀠.
CDNA synthesis for mRNA expression was performed
using Primescript RT Master Mix according to manufac-
turer’s protocol (Takara Bio, Japan). The qRT-PCR amplifica-
tion of LASP1, CAV1, FSCN1, and 𝛽-Actin (internal control)
mRNA was performed using real-time PCR 7900HT system
(Applied Biosystems, Foster City, CA) and Faststart SYBR
Green PCR Master Mix (Roche Diagnostics, Mannheim,
Germany) according to manufacturer’s instructions. The
PCR conditions were 50∘C for 2min and 95∘C for 10min,
followed by 40 cycles at 95∘C for 15 sec and 60 for 60 sec.
The expression levels of LASP1, CAV1, and FSCN1 mRNA
were normalized to𝛽-ACTINmRNAexpression.The specific
primers were as follows: LASP1, 5󸀠-CTTCGCCTCAAG-
CAACAGAGTG-3󸀠 (forward) and 5󸀠-TGTCTGCCACTA-
CGCTGAAACC-3󸀠 (reverse); CAV1, 5-CCAAGGAGATCG-
ACCTGGTCAA-3󸀠 (forward) 5󸀠-GCCGTCAAAACTGTG-
TGTCCCT-3󸀠 (reverse); FSCN1, 5-GACACCAAAAAG-
TGTGCCTTCCG-3󸀠 (forward) 5󸀠-CAAACTTGCCATTGG-
ACGCCCT-3󸀠 (reverse) and 𝛽-Actin, 5󸀠-CGAGCATCC-
CCCAAAGTT-3󸀠 (forward) 5󸀠-GCACGAAGGCTCATC-
ATT-3󸀠 (reverse).
2.3. Statistical Analysis. All relationships of the relative
expression of the target miRNA were performed using Prism
5 (Graphpad, CA, USA) statistical software. 𝑃 values are two-
sided, and 𝑃 < 0.05 were considered statistically significant.
Associations between miR-133a expression and clinicopatho-
logical features were explored using Mann-Whitney 𝑈 and
Kruskal-Wallis test, as appropriate. Survival was estimated
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using the Kaplan-Meier method and compared using the
log-rank test. Overall, metastasis-free survival and survival
curves were calculated based on date of surgery till date
of death or diagnosis of metastasis. Patients who had been
followed up for more than 2 years or until time of death
were used to calculate overall survival (OS). The expression
level was considered downregulated if the fold change was
lower than 0.40 or upregulated if more than 2.5, respectively.
The data is shown in ΔΔ form on the figures, with higher
values being indicative of lower expression, and is calculated
by normalization with internal controls and normal tissue
expression. Positive values represent downregulation. The
relative miR-133a expression is calculated using the formula
2
−(Δct). Correlation between miR-133a and potential target
genes was analyzed by Pearson’s method; the 𝑃 value was
calculated by 𝐹 test (Graphpad, CA, USA).
3. Results
3.1. Comparison of miR-133a Expression between Adjacent
Normal Mucosa and Tumorous Tissue. The expression level
of miR-133a was significantly downregulated in tumor com-
pared to adjacent nontumor mucosa (Figure 1(a), 𝑃 <
0.0001) by a mean value of 0.04-fold difference. Among the
125 samples, 104 (83.2%) cancers displayed low miR-133a
expression; of the other 21 tumors, 4 (3.2%) tumors displayed
upregulated miR-133a expression and 17 (13.6%) tumors
displayed no change in expression compared to adjacent
nontumor mucosa, suggesting that miR-133a repression was
frequently observed in CRC patients.
3.2. Reexpression of miR-133a in CRC Was Correlated with
Advanced Staging and Development of Distant Metastases.
The clinicopathological significance of miR-133a expression
was determined.Therewas no significant correlation between
miR-133a expression and other clinicopathological character-
istics, such as gender, age, tumor size, histological type, tumor
location, and depth of invasion (𝑃 < 0.05, Table 1). However,
when comparing early and late TNM clinical and Dukes
staging, a significant difference in miR-133a expression was
found, respectively (Figures 1(b) and 1(c), 𝑃 = 0.0031, 𝑃 =
0.048). Advanced TNM and Dukes staging was associated
with higher miR-133a expression even though its expression
was mostly still, lower in tumor tissues. In addition, higher
expression of miR-133a was associated with the development
of distant metastases (Figure 1(d), 𝑃 = 0.0020) in CRC
patients, indicating the significance of miR-133a in tumor
metastasis.
The prognosis of 101 CRC patients whose progress was
followed after surgical resection was also analyzed. Based
on their median value of miR-133a expression level, the out-
comes of the patientswere divided into 2 groups, high and low
miR-133a expression, and were shown to have a significant
difference using Kaplan-Meier survival analysis and Gehan-
Breslow Wilcoxon test (Figure 1(e), 𝑃 = 0.039). Patients with
a higher expression of miR-133a had a significantly lower
rate of overall survival than the patients with low miR-133a
expression.
3.3. Downregulated miR-133a Expression Was Correlated with
Several Potential Target Genes Related to Metastasis. Overall,
in 95 patients whose LASP1 and miR-133a expression were
analyzed, a negative correlation (Figure 2(a), 𝛾 = −0.23,
𝑃 = 0.024) was found, suggesting that LASP1 was indeed
negatively regulated by miR-133a in CRC. Interestingly, there
was a positive correlation between CAV1 and miR-133a
expression among CRC patients (Figure 2(b), 𝛾 = 0.27,
𝑃 = 0.0089). Additionally, there was a stronger positive cor-
relation between miR-133a and CAV1 expression in patients
who developed distant metastases (Figure 2(c), 𝛾 = 0.42,
𝑃 = 0.025). In patients who did not develop metastases,
there was a significant negative correlation between FSCN1
and miR-133a expression (Figure 2(f), 𝛾 = −0.33, 𝑃 =
0.037), but no significant associationwas observed in patients
with metastatic disease. These results indicated the complex
mechanism of target genes regulated by miR-133a, in which
the miR-133a regulatory effect was opposite to that reported
in other studies (CAV1), or even within CRC of different
metastatic potential (CAV1 and FSCN1).
4. Discussion
Even though miR-133a expression was, for the most parts,
downregulated in tumor tissue, the higher expression among
patients correlated with poor prognosis and adverse clinical
characteristics. The correlation of miR-133a expression with
the development of distant metastases as well as advanced
TNM and Dukes staging indicates that miR-133a expression
is associated with metastasis and hence tumour progression
of CRC.
Many functional studies have been conducted on miR-
133a and its experimentally proven oncogene targets, suggest-
ing its role as a tumor suppressor in various cancers [9, 13, 14].
However, limited studies have been conducted on correlation
between clinical data and miR-133a expression in large
cohorts of patients, indicating a lack of clinicopathological
knowledge regarding miR-133a in CRC and limited attempts
to identify its direct targets in clinical samples. In molecular
studies, miR-133a has been shown to directly regulate several
metastasis-related oncogenes, including FSCN1 in bladder
cancer [9], LASP1 in CRC [11], and CAV1 in head and neck
squamous cell carcinoma [15]. There are conflicting reports
regarding the role of miR-133a in cancer progression as gain-
of-function studies have been shown to inhibitmetastasis and
tumorigenesis using molecular studies and animal models in
CRC [6].
This study found that CAV1 was not directly targeted by
miR-133a in CRCs as there was an overall positive correlation
between their miR-133a and CAV1 expression (Figure 2(b),
𝛾 = 0.27, 𝑃 = 0.0089), and even stronger correlation in
patients who developed distant metastases (Figure 2(d), 𝛾 =
0.42, 𝑃 = 0.025). This change in correlation between CAV1
and miR-133a expression implies dysregulation of either one
or both of these genes, providing additional evidence to
previous papers regarding the reexpression of CAV1 increas-
ing metastatic and migratory potential. The evidence for
the dysregulation of miR-133a during metastasis is similar
4 Disease Markers
P < 0.0001 (n = 125)
Normal Tumor
0.0
0.2
0.4
0.6
0.8
Re
lat
iv
e m
iR
-1
33
a e
xp
re
ss
io
n
(a)
I/II (n = 60) III/IV (n = 62)
TNM staging
−5
0
5
10
15
P = 0.0031
Δ
Δ
m
iR
-1
33
a
(b)
−5
P = 0.048
0
5
10
15
A/B (n = 42) C/D (n = 36)
Dukes
Δ
Δ
m
iR
-1
33
a
(c)
−5
P = 0.0020
N (n = 95) Y (n = 28)
0
5
10
15
Distant metastasis
Δ
Δ
m
iR
-1
33
a
(d)
0 20 40 60 80
60
70
80
90
100
110
High miR-133a (n = 52)
Low miR-133a (n = 51)
P = 0.039
Time (months)
Su
rv
iv
al
 (%
)
(e)
Figure 1: MiR-133a expression in colorectal cancer. (a) Comparison of miR-133a expression levels in 125 patients between colorectal cancer
tissue and adjacent normalmucosa.The expression levels were normalized usingU6 as an internal control.𝑃 value was calculated by Student’s
𝑡-test. MiR-133a expression levels were downregulated in cancer tissue than in normal adjacent mucosa (𝑃 < 0.0001); (b) and (c) correlation
between miR-133a expression and TNM and Dukes stage in patients with colorectal cancer: (b) Dukes stage (𝑃 = 0.048), (c) TNM stage
(𝑃 = 0.0031). (d) Correlation between miR-133a expression and development of distant metastases in 123 patients with colorectal cancer.
Difference was significant between development of distant metastases (Y) and no development of distant metastases (N): (𝑃 = 0.002). (e)
Five-year Kaplan-Meier survival curves according to the level of miR-133a expression for colorectal. There were 103 colorectal patients that
were classified into two groups according to the median miR-133a expression level as determined by qRT-PCR. MiR-133a expression was
normalized to U6, an internal control. High expression group of miR-133a was correlated with significantly poorer prognosis, that is, survival
rate, than in the low expression group (𝑃 = 0.039), n = number of patients. A higher ΔΔ value indicates lower expression and positive values
represent downregulation 1. Relative miR-133a expression is calculated using the formula 2−(ΔCT).
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Table 1: Association of clinicopathological factors in colorectal cancer patients and expression of mir-133a in tumor tissue. A higherΔΔ value
indicates lower expression; positive values represent downregulation.
Variables Patients, 𝑛 MiR-133a expression 𝑃 value†
(𝑛 = 125)a Mean ΔΔ value ± SD
Age 0.938
≤65 36 4.440 ± 0.4927
>65 89 4.488 ± 0.3301
Gender 0.977
Male 73 4.517 ± 0.3569
Female 51 4.501 ± 0.4332
Dukes 0.0481∗
A, B 42 5.139 ± 0.5392
C, D 36 3.716 ± 0.4348
Tumor size 0.2643
<5 cm 68 4.739 ± 0.3548
≥5 cm 55 4.124 ± 0.4228
Histological type 0.3664
Well, moderate 78 4.681 ± 0.3499
Poor, mucinous 5 3.395 ± 1.172
Depth of invasion 0.2158
T1, T2 16 5.400 ± 0.7513
T3, T4 100 4.352 ± 0.3146
TNM stage 0.0031∗
I, II 60 5.316 ± 0.3887
III, IV 62 3.667 ± 0.3835
Location 0.9658
Colon 90 4.527 ± 0.3259
Rectum 32 4.554 ± 0.5298
Lymph node metastasis 0.0595
Absent 68 4.926 ± 0.3629
Present 55 3.893 ± 0.4034
Distant metastasis 0.0020∗
Absent 95 4.983 ± 0.3188
Present 28 2.932 ± 0.5104
aThe total number of cases may be less than 125 as some information was unavailable.
†
𝑃 values are based on Student’s 𝑡-test.
SD: standard deviation; ∗𝑃 < 0.05.
to CAV1 in that it is reactivated during metastasis since its
expression changes during tumor progression [16–18]. CAV1
has been characterized to possess a dual-function in cancer
progression as a tumor suppressor and oncogene, and its
reexpression has been implied to be necessary for metastasis
in certain types of cancer to promote cell migration and
invasion, for example, breast, lung, and prostate [19–21].
These reactivation and upregulation have been indicative of
more aggressive and chemoresistant phenotypes in some can-
cers with poor prognosis [22, 23]. The contrasting functions
for CAV1 were partially explained by Williams and Lisanti
who observed CAV1 to possess several peptides regions
with different roles [16]. Previously, CAV1 has been reported
to be downregulated in CRC and possessed “differential
biphasic expression” which supports the findings that CAV1
is positively correlated with miR-133a in CRC patients,
particularly in those who developed distant metastases, since
advanced tumor progression and metastasis were associated
with higher miR-133a expression as demonstrated in this
study [17, 18, 24].
MiR-133a expression was found to be inversely correlated
with LASP1 expression (Figure 2(a), 𝛾 = −0.23, 𝑃 =
0.024) corroborating the previous study by Wang et al.
regarding LASP1 being a direct target of miR-133a in CRC in
their functional study involving an orthotropic model [25].
Interestingly, LASP1 gene has previously been reported to
be overexpressed in CRC possessing a functional role in
tumor metastasis and progression, and its overexpression
in metastatic breast and ovarian cancer further supported
this [11, 26]. On the contrary, FSCN1 was only found
to be negatively correlated in patients who have not yet
developed metastases (Figure 2(f), 𝛾 = −0.33, 𝑃 = 0.037),
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Figure 2: Correlation of miR133a and its potential target genes in colorectal cancer. (a) There was a significant negative correlation shown
between miR-133a and LASP1 mRNA expression: 𝑃 = 0.024, 𝛾 = −0.23, (𝑛 = 95). (b)–(d): (b) An overall significant correlation was found
betweenmiR-133a and CAV1mRNA expression level: 𝑃 = 0.0089, 𝛾 = 0.27, (𝑛 = 91), (c) nonmetastatic: 𝑃 = 0.068, 𝛾 = 0.23, (𝑛 = 66), and (d)
metastatic, a stronger positive correlation was determined between patients whom develop distant metastases: 𝑃 = 0.025, 𝛾 = 0.42, (𝑛 = 28).
(e)–(g): (e) overall: 𝑃 = 0.037, 𝛾 = −0.33, (𝑛 = 63), (f) nonmetastatic, a significant negative correlation was shown between miR-133a and
FSCN1 mRNA expression levels that have not yet developed metastases: 𝑃 = 0.037, 𝛾 = −0.33, (𝑛 = 41), (g) metastatic: 𝑃 = 0.56, 𝛾 = 0.13,
(𝑛 = 24), n = number of patients. Higher ΔΔ values indicate lower expression; positive values represent downregulation.
suggesting that FSCN1 is dysregulated by miR-133a and its
suppression impaired metastasis. FSCN1 has been proven to
be a metastatic gene and target of miR-133a in esophageal
squamous cell carcinoma and bladder cancer [9, 10]. The
functional role documented by many papers indicates that
it is generally involved in the migration and invasion and,
therefore, involved in the seeding of circulating tumor cells
to metastatic sites, hence explaining its suppression by miR-
133a in nonmetastatic patients [27, 28]. In CRC, miR-451 has
also been proven to mediate FSCN1 expression by inhibiting
5󸀠 AMP-activated protein kinase (AMPK) when overex-
pressed, which in turn activates the mammalian target of
rapamycin (mTOR) that is capable of regulating FSCN1 [29].
This indicates that at least two microRNAs regulate FSCN1
expression in CRC, providing an explanation why miR-133a
expression correlates with FSCN1 only in nonmetastatic CRC
patients.
Higher expression of miR-133a has also been linked to
increased metastasis in research conducted by Nohata et
al., who found miR-133a to be a promoter of genes related
to increased brain metastasis in CRC [30]. Based on this
previous paper, themiR-133a expression not only increases in
the primary tumor but also in the metastases, in which miR-
133a expression is higher than the primary.
Higher expression of MiR-133b, a homologue of miR-
133a which shares the same transcription unit, was shown
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to be associated with poorer survival when compared to
low expression in 106 bladder cancer patients (𝑃 < 0.001)
indicating the potential for this group of miRNAs to function
as oncomirs [31]. MiR-133a and miR-133b have been shown
to both target FSCN1 in esophageal squamous cell carcinoma
that could potentially be mirrored in CRC as they share sev-
eral other potential target genes due to their high similarity
in sequence, that is, only differing by one nucleotide [10, 30].
In this study, higher expression of miR-133a significantly
correlated with the shorter OS in a 5-year survival analysis
of 102 CRC patients, indicating the potential of miR-133a
as a prognostic marker in CRC therapy. High expression
seemed to be a significant predictor for poor prognosis and
development of metastasis. MiR-133a was found to be upreg-
ulated in 5-fluorouracil chemoresistant cells and potentially
possess a higher proportion of cells with cancer stem cell
phenotype and therefore possess a highermetastatic potential
based on Dallas et al. [31, 32]. Interestingly, the expression of
miR-133a was also found to be upregulated in CRC patient’s
plasma samples compared to neoplasm-free controls, which
also contradicts many tissue-based studies, indicating that
miR-133a is not simply a tumor suppressor as many papers
reported [33].
In conclusion, the expression of miR-133a is downregu-
lated during CRC carcinogenesis, but its high expression in
tumor tissues is correlated with advanced Dukes and TNM
stage, development of distant metastasis, and poor prognosis.
Therefore, miR-133a possesses the potential to function as
a clinical marker to identify patients with aggressive CRC
whose survival rate is likely to be low and who are prone
to develop distant metastases. Also, miR-133a expression was
negatively correlated with FSCN1 expression in patients who
did not develop distant metastases, but positively correlated
with CAV1 expression in patients who did develop distant
metastases. This indicates that the role of miR-133a is much
more complicated than simply a tumor suppressor. Further
research is required to understand the role of miR-133a
in tumor progression and its complicated interactions with
oncogenes and tumor suppressors.
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